Kalray Wins Flash Memory Summit Award for the Second Year in a Row
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for the high-performance, data-centric computing and storage markets, has been recognized as the leader of the DPU category in the 17th Annual Flash Memory Summit Awards competition.
Flash Memory Summit (FMS) is the world’s largest international comprehensive memory and storage showcase, hosted at the Santa Clara Convention Center, California, USA. The new Kalray K220-LP Storage Acceleration Card, powered by Kalray's 3rd generation DPU processor, won the FMS Award in the DPU category. This Flash Memory Summit Award symbolizes the industry's acknowledgment of the innovation and business value that Kalray solutions bring to the market.
KALRAY UNVEILS ITS NEW K220-LP™ SMART STORAGE ACCELERATOR
Kalray’s K220-LP™ Smart Storage Accelerator (SSA) was introduced at FMS this year, bringing storage offload to the next level. By offloading intensive storage data services from the main CPU, the SSA releases all the potential of NVMe SSDs in any server with local NVMe devices. The main CPU is freed to perform billable tasks while all storage-related tasks are offloaded to the Kalray K220-LP™ Smart Storage Accelerator.
“Customers have a need to maximize their server investments by pursuing greater optimization and performance. This can be achieved by offloading storage data services to specialized processors for maximum ROI of the server infrastructure,” said Jay Kramer, chairman of the awards program and president of Network Storage Advisors Inc. “We are proud to recognize Kalray’s Smart Storage Accelerators for their ability to efficiently store both data and metadata on storage class memory (SCM) while offloading storage data services and applications from the main CPU. This solution enables customers to realize the full potential of local NVMe SSDs deployed in any industry-standard server.”
KALRAY DEMONSTRATES THAT QLC MEMORY ADOPTION BENEFITS DATA CENTERS
As a powerful use case, Kalray demonstrated how its solution allows a new generation of SSDs, called QLC SSDs, to be adopted into data centers without requiring any changes to the data center operating system, file system, or applications. Kalray DPUs have accelerators, fast coherent memory, and flexible programmability, which makes them ideal for storage management functions such as managing new QLC technology. Thanks to Kalray’s solution, data centers can take full advantage of the price, capacity, and performance benefits of QLC flash devices. The result is a data center that realizes the benefits of QLC without performance and durability penalties and without the need to modify existing software.
“QLC SSDs present great economic advantages by delivering greater capacity and density. But compared to other SSD types, QLC technology has challenges to overcome, including lower endurance, higher latency, and reduced performance under heavy workloads,” added Jay Kramer. “We are proud to recognize Kalray’s Smart Storage Accelerators for their highly effective performance in enabling a simple deployment on industry-standard servers. This solution allows customers to achieve cost and capacity benefits of QLC devices transparently, with no hardware architectural changes and no software stack changes.”
ACKNOWLEDGEMENT OF THE SOLUTION’S INNOVATION
“It is a great honor to win a Flash Memory Summit award for the second year in a row,” said Éric Baissus, chief executive officer of Kalray. “This award represents strong recognition of the value of our solutions. Customers who integrate our new K220-LP™ SSA into their servers can accelerate the transition from traditional storage architectures relying on SAS (Serial Attached SCSI) to high-performance, power-efficient NVMe-based solutions.”
The K220-LP™ solution includes Kalray’s AccessCore® Storage (ACS) software SDK. Thanks to ACS SDK, the K220-LP™ SSA is fully programmable, enabling offload of custom storage or computational application processing, thus removing the usual bottlenecks of traditional architectures. The Kalray solution enables data centers to leapfrog outdated technologies that are unable to sustain the storage requirements of demanding workloads and embrace the benefits of modern, scalable, and flexible data solutions with minimal effort.
This is the second consecutive award Kalray has received from Flash Memory Summit, maintaining momentum in innovation following last year’s award for most innovative technology with Flashbox™.
ABOUT KALRAY
Kalray (Euronext Growth Paris – FR0010722819 – ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Kalray’s offerings include unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as leading-edge software-defined storage and data management solutions. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers and to design the best solutions in fast-growing sectors such as AI, media & entertainment, life science, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. Visit us at www.kalrayinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809063602/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS finance & communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Tel. 01 53 67 36 72
PRESS
Diana EADINGTON
communication@kalrayinc.com
Tel. +44 7939 877 880
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom